$INTI
Inhibitor Therapeutics, Inc.

2016 Q4 Form 10-Q Financial Statement

#000119312516752501 Filed on October 31, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.030M $1.010M $570.0K
YoY Change 256.14% 68.33% -3.39%
% of Gross Profit
Research & Development $730.0K $720.3K $470.0K
YoY Change 55.32% 19.72% 51.61%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.760M $1.734M $1.030M
YoY Change 167.96% 44.27% 14.44%
Operating Profit -$1.734M
YoY Change 44.27%
Interest Expense $10.00K $10.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.750M -$1.730M -$1.030M
YoY Change 166.99% 44.17% 14.44%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.750M -$1.725M -$1.030M
YoY Change 166.99% 43.5% 14.44%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.01 -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 300.4M shares 300.4M shares 245.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.890M $3.550M $600.0K
YoY Change 1048.33% 186.29% 62.16%
Cash & Equivalents $6.885M $3.554M $601.4K
Short-Term Investments
Other Short-Term Assets $310.0K $58.90K $34.41K
YoY Change 800.8% -1.83% -64.82%
Inventory
Prepaid Expenses $61.10K $34.41K
Receivables
Other Receivables
Total Short-Term Assets $7.197M $3.613M $635.9K
YoY Change 1031.78% 177.93% 37.34%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $141.6K $250.0K $250.0K
YoY Change -43.37% 0.0%
Total Long-Term Assets $141.6K $250.0K $250.0K
YoY Change -43.37% 0.0%
TOTAL ASSETS
Total Short-Term Assets $7.197M $3.613M $635.9K
Total Long-Term Assets $141.6K $250.0K $250.0K
Total Assets $7.338M $3.863M $885.9K
YoY Change 728.36% 149.23% 91.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $297.8K $441.5K $383.4K
YoY Change -22.31% -0.14% 17.97%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $308.1K $469.6K $461.9K
YoY Change -33.29% -13.1% 15.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $308.1K $469.6K $461.9K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $308.1K $469.6K $461.9K
YoY Change -33.29% -13.1% 15.21%
SHAREHOLDERS EQUITY
Retained Earnings -$43.17M -$40.42M -$36.17M
YoY Change 19.35% 15.03% 12.26%
Common Stock $50.20M $43.81M $36.60M
YoY Change 37.18% 21.2% 13.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.030M $3.393M $424.0K
YoY Change
Total Liabilities & Shareholders Equity $7.338M $3.863M $885.9K
YoY Change 728.36% 149.23% 91.34%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q4
OPERATING ACTIVITIES
Net Income -$2.750M -$1.725M -$1.030M
YoY Change 166.99% 43.5% 14.44%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.210M -$1.060M -$640.0K
YoY Change 89.06% 63.08% 23.08%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.540M 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.210M -1.060M -640.0K
Cash From Investing Activities
Cash From Financing Activities 4.540M 0.000 0.000
Net Change In Cash 3.330M -1.060M -640.0K
YoY Change -620.31% 63.08% 6300.0%
FREE CASH FLOW
Cash From Operating Activities -$1.210M -$1.060M -$640.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
300438270 shares
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1243272
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
300353270 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
300353270 shares
CY2016Q3 us-gaap Assets
Assets
3862736
CY2016Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
3200000
CY2016Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2016Q3 us-gaap Assets Current
AssetsCurrent
3612736
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
469603
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
3393133
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40421017
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43784115
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3553832
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
30035
CY2016Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
441489
CY2016Q3 us-gaap Other Assets Current
OtherAssetsCurrent
58904
CY2016Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
28114
CY2016Q3 us-gaap Liabilities
Liabilities
469603
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3862736
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
100000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
365161
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
245353270 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
245353270 shares
CY2015Q4 us-gaap Assets
Assets
885859
CY2015Q4 us-gaap Assets Current
AssetsCurrent
635859
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36571982
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
601445
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
24535
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
383356
CY2015Q4 us-gaap Other Sundry Liabilities
OtherSundryLiabilities
52500
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
34414
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
78524
CY2015Q4 us-gaap Liabilities
Liabilities
461880
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
885859
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
461880
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
423979
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36172538
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
878111
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1701422
us-gaap Operating Expenses
OperatingExpenses
2916391
us-gaap Net Income Loss
NetIncomeLoss
-2916391
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
229507
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
208794
us-gaap Operating Income Loss
OperatingIncomeLoss
-2916391
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2500000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1621889
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1214969
us-gaap Share Based Compensation
ShareBasedCompensation
1273789
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
228324455 shares
hppi Issuance Of Common Stock In Payment Of Trade Payable
IssuanceOfCommonStockInPaymentOfTradePayable
90000
hppi Proceeds From Issuance Of Common Stock Related Parties
ProceedsFromIssuanceOfCommonStockRelatedParties
2500000
dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
1716309
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2952387
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2350337
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Revenues
Revenues
0
us-gaap Operating Expenses
OperatingExpenses
4258709
us-gaap Net Income Loss
NetIncomeLoss
-4248479
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
7723
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
24490
us-gaap Operating Income Loss
OperatingIncomeLoss
-4258709
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
10230
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5501324
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2548937
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2664900
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2664900
dei Trading Symbol
TradingSymbol
HPPI
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1908372
us-gaap Share Based Compensation
ShareBasedCompensation
1716309
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
273979411 shares
hppi Stock Issued During Period Value New Issues To Related Party
StockIssuedDuringPeriodValueNewIssuesToRelatedParty
2836424
hppi Issuance Of Common Stock In Payment Of Trade Payable
IssuanceOfCommonStockInPaymentOfTradePayable
0
hppi Proceeds From Issuance Of Common Stock Related Parties
ProceedsFromIssuanceOfCommonStockRelatedParties
2836424
CY2016Q2 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
25000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1013846
CY2016Q3 us-gaap Revenues
Revenues
0
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
1734185
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-1725008
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1734185
CY2016Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
9177
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
720339
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
300353270 shares
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
600397
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
1202061
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-1202061
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1202061
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
601664
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
245353270 shares

Files In Submission

Name View Source Status
0001193125-16-752501-index-headers.html Edgar Link pending
0001193125-16-752501-index.html Edgar Link pending
0001193125-16-752501.txt Edgar Link pending
0001193125-16-752501-xbrl.zip Edgar Link pending
d263307d10q.htm Edgar Link pending
d263307dex311.htm Edgar Link pending
d263307dex312.htm Edgar Link pending
d263307dex321.htm Edgar Link pending
d263307dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20160930.xml Edgar Link completed
hppi-20160930.xsd Edgar Link pending
hppi-20160930_cal.xml Edgar Link unprocessable
hppi-20160930_def.xml Edgar Link unprocessable
hppi-20160930_lab.xml Edgar Link unprocessable
hppi-20160930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending